What is Immunome Inc (IMNM) stock price today?

Immunome Inc (IMNM) currently trades at $22.95 per share. The stock has a market capitalization of $2.60B and a P/E ratio of —x.

Is IMNM stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Immunome Inc has a Smart Value Score of 24/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -3.24.

What is Immunome Inc's revenue and earnings?

Immunome Inc has trailing twelve-month (TTM) revenue of $6.94M with profit margins of 0.00%. Earnings per share (EPS) is $-2.43.

Is Immunome Inc financially healthy?

Immunome Inc's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -3.24 places it in the distress.

IMNM

Immunome Inc

NASDAQ: IMNM · HEALTHCARE · BIOTECHNOLOGY

$22.95

-3.21% today

Updated 2026-04-29

Market cap

$2.60B

P/E ratio

—

P/S ratio

374.45x

EPS (TTM)

$-2.43

Dividend yield

—

52W range

$7 – $28

Volume

1.2M

Market cap

$2.60B

P/E ratio

—

P/S ratio

374.45x

EPS (TTM)

$-2.43

Dividend yield

—

52W range

$7 – $28

Volume

1.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.3

Growth

6.5

Quality

2.5

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-3.2

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$35.17

+53.25%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy12 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.02x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -3.24 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-51.95M

- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$6.63M	$14.02M	$9.04M	$6.94M	$6.94M
Net income	$-36.90M	$-106.81M	$-292.96M	$-212.39M	$-69.90M
EPS	—	—	—	—	$-2.43
Free cash flow	$-28.94M	$-8.40M	$-164.30M	$-200.60M	$-51.95M
Profit margin	-556.75%	-761.92%	-3,240.38%	-3,059.99%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
IMNM	$2.60B	24	3.3	2.5	5.0	6.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Immunome Inc trades at $22.95. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -3.24, it sits in the distress. TTM revenue stands at $6.94M.

Frequently asked questions

What is Immunome Inc's stock price?

Immunome Inc (IMNM) trades at $22.95.

Is Immunome Inc overvalued?

Smart Value Score 24/100 (Grade F, Strong Sell).

What is the price target of Immunome Inc (IMNM)?

The analyst target price is $35.17, representing +53.2% upside from the current price of $22.95.

What is Immunome Inc's revenue?

TTM revenue is $6.94M.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-3.24 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

immunome.com

Quick metrics

P/S ratio374.45x

ROE-52.10%

Beta2.14

50D MA$21.86

200D MA$17.49

Shares out0.11B

Float0.09B

Short ratio—

Avg volume1.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

IMNM vs LLY →IMNM vs JNJ →IMNM vs ABBV →Stock screener →